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Abstract
Background: Over-activation of TGFb signaling pathway and uncontrolled cell proliferation of hepatic stellate cells (HSCs)
play pivotal roles in liver fibrogenesis, while the protein serine/threonine phosphatase PP2Ca was reported to negatively
regulate TGFb signaling pathway and cell cycle. Our study aimed to investigate the role of PP2Ca in liver fibrogenesis.
Methodology/Principal Findings: The effects of PP2Ca activation on liver fibrosis were investigated in human HSCs and
primary rat HSCs in vitro using western blotting, real-time PCR, nuclear translocation, cell viability and cell cycle analyses.
The antifibrogenic effects in carbon tetrachloride (CCl4)- and bile duct ligation (BDL)-induced mice in vivo were assessed
using biochemical, histological and immunohistochemical analyses. The results demonstrated that activation of PP2Ca by
overexpression or the new discovered small molecular activator NPLC0393 terminated TGFb-Smad3 and TGFb-p38 signaling
pathways, induced cell cycle arrest in HSCs and decreased a-smooth muscle actin (a-SMA) expression, collagen deposition
and hepatic hydroxyproline (HYP) level in CCl4- and BDL-induced mice.
Conclusions/Significance: Our findings suggested that PP2Ca activation might be an attractive new strategy for treating
liver fibrosis while the small molecular activator NPLC0393 might represent a lead compound for antifibrogenic drug
development. Moreover, our study might provide the first evidence for the role of PP2C family members in the fibrotic
disease.
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Introduction
Liver fibrosis is a major public health threat causing portal
hypertension, liver failure, and risk of hepatocellular carcinoma.
Hepatic stellate cells (HSCs) play critical roles in liver
fibrogenesis. Once intoxicated by stimuli, quiescent HSCs could
transdifferentiate into activated HSCs which secrete some
proinflammatory and profibrogenic cytokines such as tumor
necrosis factor alpha (TNFa) and transforming growth factor beta
(TGFb), leading to over-accumulation of extracellular matrix
(ECM) and altered matrix degradation. Meanwhile, these
cytokines further activate HSCs and enhance their proliferation
and survival, thus exacerbating fibrogenesis [1]. Recently,
emerging strategies against liver fibrosis have been proposed,
such as selective antagonization of CB1 cannabinoid receptor [2],
targeting 5-hydroxytryptamine (5-HT) class of receptors [3],
inhibition of Toll-like receptor 4 (TLR4) [4], and activation of
STAT1 [5], etc. However, the efficient strategies are still lacking
due to the complicated pathogenesis associated with this disease
[6].
Protein serine/threonine phosphatases (PS/TPs) dephosphory-
late phosphoserine/phosphothreonine-containing proteins and
comprise three structurally distinct families: phosphoprotein
phosphatases (PPPs), metal-dependent protein phosphatases
(PPMs), and the aspartate-based phosphatases represented by
FCP/SCP (TFIIF-associating component of RNA polymerase II
CTD phosphatase/small CTD phosphatase). Protein phosphatase
2C, which belongs to PPM family, is a structurally and functionally
distinct group of enzymes that currently contain about 22 different
family members. The members of this family are distinguished by
their monomeric property and dependency on Mg
2+ and Mn
2+
[7]. It should be noted that except the oncoprotein PP2Cd (also
known as Wip1) [8,9], all the other members from this family have
been identified as tumor suppressors based on their inhibition of
cell growth and cellular stress signaling [10,11].
Protein phosphatase 2C alpha (PP2Ca; EC 3.1.3.16), the most
extensively characterized member of PP2C family, plays an
important role in TGFb, cell growth, stress and inflammation
signaling [10,12–15]. PP2Ca was reported to dephosphorylate
Smad2/Smad3 to block TGFb signaling pathway [12], activate
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[13,14], inhibit p38 and JNK signaling pathways to prevent stress
[16] and dephosphorylate IKappa B kinase b (IKKb) to prevent
inflammatory response [15]. Recently, the potential role of PP2Ca
in tumorigenesis has been revealed [11], whereas its function in
the fibrotic disease still remains unknown. The current study
therefore aimed to investigate the role of PP2Ca in liver fibrosis by
assessing the effects on TGFb signaling pathway and cell cycle of
HSCs and ECM expression in mouse models. Our findings suggest
that PP2Ca activation might be a promising new strategy for the
treatment of liver fibrosis.
Results
Activation of PP2Ca inhibited TGFb-Smad3 and TGFb-
p38 signaling pathways in HSCs
Since Smad3 was regarded as the main mediator of TGFb-
induced fibrotic response [12,17], we first assessed the impact of
PP2Ca on TGFb-induced Smad3 phosphorylation in human
hepatic stellate cell line LX-2 cells. As shown in Figure 1A, TGFb
stimulated Smad3 phosphorylation, while the stimulation was
obviously decreased after PP2Ca overexpression and slightly
enhanced with PP2Ca knock-down by shPP2Ca494. Similarly,
the TGFb-induced Smad2 phosphorylation was reduced with
PP2Ca overexpression and mildly increased with PP2Ca knock-
down. Considering that p38 was also reported to mediate TGFb-
induced fibrotic effects [16,18], we examined the effect of PP2Ca
on TGFb-induced p38 phosphorylation. The result revealed that
TGFb stimulated the phosphorylation of p38 and this stimulation
could be regulated by PP2Ca overexpression or knock-down
(Figure 1A).
We next studied whether PP2Ca affected TGFb-induced
collagen transcription that was reported to be up-regulated by
Smad3 and p38 phosphorylations [17,18]. Consistently, the results
indicated that TGFb increased a1(I) procollagen mRNA tran-
scription, whereas PP2Ca overexpression aborted the stimulatory
effect of TGFb while PP2Ca knock down enhanced it (Figure 1B).
These findings demonstrated that overexpression of PP2Ca
suppressed TGFb-Smad3 and TGFb-p38 signaling pathways in
HSCs.
Activation of PP2Ca induced cell cycle arrest in HSCs
The regulation of PP2Ca on cell cycle in several cell lines was
reported previously [11,13,14]. Consistent with these reports, our
work demonstrated that overexpression of PP2Ca inhibited LX-2
cell viability in a dose-dependent manner (Figure 1C).
Cdk2, an important regulatory protein of G1-S transition, was
reported to mediate PP2Ca induced cell cycle arrest [13].
Therefore, to verify whether the cell viability loss was due to cell
cycle arrest induced by PP2Ca, we examined Cdk2 phosphory-
lation. The result (Figure 1D) indicated that overexpression of
PP2Ca attenuated Cdk2 phosphorylation, while knock down of
PP2Ca enhanced it. These results suggested that PP2Ca induced
cell cycle arrest in LX-2 cells through down-regulating Cdk2
phosphorylation.
Identification of NPLC0393 as a small molecular PP2Ca
activator
To further verify the therapeutic potential of PP2Ca,w e
identified a small molecular PP2Ca activator, NPLC0393,
through a reconstituted in vitro PP2Ca phosphatase assay
(Figure 2A) [19]. The result revealed that NPLC0393 dose-
dependently increased PP2Ca activity with an EC50 value of
6.72 mM using pNPP as substrate (Figure 2B). Additionally, we
further confirmed the enhancement of PP2Ca activity by
NPLC0393 using the phosphopeptide substrate FLRTpSCG,
which is derived from AMP-activated protein kinase and was
previously reported to be a good substrate for PP2Ca [14]. The
result indicated that NPLC0393 also increased PP2Ca activity in a
dose-dependent manner, with an EC50 value of 6.43 mM
(Figure 2C).
Subsequently, we confirmed the direct binding of NPLC0393 to
PP2Ca through surface plasmon resonance (SPR) technology
based assay. The dissociation equilibrium constant (KD) was thus
determined as 19.2 mM (Figure 2D). In addition, the isothermal
titration calorimetry (ITC) was also applied to analyze the
stoichiometry and thermodynamics of NPLC0393/PP2Ca inter-
action by titrating NPLC0393 to PP2Ca (Figure 2E). The results
revealed that the stoichiometric ratio was 1.0560.03, implying
that a single molecule of NPLC0393 could interact with one
molecule of PP2Ca. Furthermore, the determined KD was
approximately 14.7 mM, similar to the SPR result. Notably, the
change in Gibbs’ free energy (DG) resulting from NPLC0393/
PP2Ca interaction was driven primarily by a favorable entropy
(TDS, 5.93 kcal/mol), compared with the enthalpy (DH,
20.669 kcal/mol), suggesting that NPLC0393/PP2Ca binding
was mainly mediated by the increase of the buried surface area
rather than the polar interactions (Figure 2E).
To assess the targeting specificity of NPLC0393, we evaluated
the effects of NPLC0393 on two representative mammalian Ser/
Thr phosphatases (PP1 and PP2A) and one typical Tyrosine
phosphatase (PTP1B). The results in Table 1 thereby indicated
that NPLC0393 had no obvious activities against these three tested
phosphatases, further suggesting its good specificity against
PP2Ca.
Collectively, our results demonstrated that NPLC0393 as a
specific small molecular activator of PP2Ca might be used as a
potential probe to elucidate the biological significance of PP2Ca in
relevant diseases.
NPLC0393 inhibited TGFb-Smad3 and TGFb-p38
signaling pathways in HSCs
The effects of NPLC0393 on TGFb-Smads and TGFb-p38
signaling pathways were assessed in LX-2 cells and primary rat
hepatic stellate cells (HSCs). The results indicated that NPLC0393
decreased Smad3 phosphorylation in both time- and dose-
dependent manners (Figure 3A), and the TGFb-induced Smad3
and p38 phosphorylations were also reduced by NPLC0393
treatment (Figure 3B). Moreover, NPLC0393 inhibited Smad3
nuclear localization (Figure 3C), which was reported to depend on
its phosphorylation [12]. Additionally, it should be pointed out
that NPLC0393 rendered no evident influence on basal or
TGFb-induced Smad2 phosphorylation (Figure 3A,B). Finally,
NPLC0393 decreased basal and TGFb-induced a1(I) procollagen
mRNA expression (Figure 4A,B). Furthermore, NPLC0393 failed
to exert the above effects in PP2Ca stable knock-down cells
(shPP2Ca cells) (Figure 4C,D), thus confirming that these effects of
NPLC0393 were mediated by PP2Ca. Altogether, these findings
indicated that treatment of NPLC0393 could block TGFb-Smad3
and TGFb-p38 signaling pathways through inhibiting Smad3 and
p38 phosphorylations and Smad3 nuclear localization.
NPLC0393 induced cell cycle arrest in HSCs
The impact of NPLC0393 on cell cycle was also examined in
LX-2 and primary rat HSCs cells. As indicated in Figure 5A and
B, NPLC0393 decreased HSCs cell viability in a time- and dose-
dependent manner as assessed by MTT assay. To figure out
whether such cell viability reduction was due to cell cycle arrest,
PP2Ca Prevents Liver Fibrosis
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demonstrated that 48h incubation of NPLC0393 dose-dependent-
ly induced G1 phase arrest in LX-2 cells (Figure 5C,D). Analysis of
cell cycle regulatory proteins revealed that NPLC0393 decreased
phosphorylation of Cdk2 in LX-2 cells (Figure 5E, left).
Considering that Platelet-Derived Growth Factor (PDGF) could
stimulate cell proliferation by increasing Cdk2 phosphorylation
[20], we also examined the effect of NPLC0393 on PDGF-induced
p-Cdk2 level in LX-2 cells. The result displayed that NPLC0393
obviously inhibited PDGF-induced Cdk2 phosphorylation in a
dose-dependent manner (Figure 5E, right). Moreover, the effects
of NPLC0393 on cell cycle were subsequently studied in shPP2Ca
cells. The results showed that NPLC0393 failed to decrease cell
viability (Figure 5F) and Cdk2 phosphorylation (Figure 5G) in
Figure 1. Activation of PP2Ca inhibited both TGFb-Smad3 and TGFb-p38 signaling pathways and induced cell cycle arrest in HSCs.
(A) Flag-hPP2Ca, shPP2Ca494 and control vectors were electransfected into LX-2 cells. At 48 h post-transfection, 2 ng/ml of TGFb was used to
stimulate the cells for 1 h. Cells were harvested and proteins were immunoblotted with the indicated antibodies. (B) At 24 h post-transfection with
hPP2Ca and shPP2Ca494, LX-2 cells were stimulated with TGFb (2ng/ml) for another 24 h. Cells were harvested for real-time PCR experiment.
#P,0.001 compared with non-TGFb-treated group; *P,0.05, **P,0.01 compared with TGFb-treated group tranfected with control vector. (C) Cell
viability was assessed by MTT assay at 48 h post-transfection with increasing concentrations of hPP2Ca (upper panel). Increasing expressions of
PP2Ca were verified by western blotting (lower panel). (D) Cells were harvested at 48 h post-transfection with hPP2Ca and shPP2Ca494 and total cell
extracts were analyzed by western blotting.
doi:10.1371/journal.pone.0014230.g001
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findings indicated that activation of PP2Ca by NPLC0393
induced cell cycle arrest in HSCs.
NPLC0393 attenuated liver fibrogenesis in vivo
To further investigate the anti-liver fibrosis potential of PP2Ca,
two different mouse models bearing liver fibrosis were treated with
the PP2Ca activator NPLC0393. Compared with the vehicle
group, treatment of NPLC0393 (2.5 mg/kg) rendered no obvious
influence on the serum alanine transaminase (ALT), aspartate
transaminase (AST) levels or the liver histology, implying that
NPLC0393 was little toxic in vivo (data not shown). As shown in
Figure 6A and B, 2.5 mg/kg of NPLC0393 administration
decreased a-SMA expression in both CCl4 and BDL-induced
liver fibrosis mice. In addition, Masson staining of collagen
indicated that NPLC0393 reduced the fibrosis area in both models
(Figure 7A). The CCl4 and BDL-induced a1(I) procollagen mRNA
levels were also decreased in the NPLC0393-treated mice
(Figure 7B). Moreover, NPLC0393 administration declined the
ECM marker, hydroxyproline (HYP) content in the two kinds of
liver fibrosis mice (Figure 7C). It should be also noted that
NPLC0393 decreased the ALT and AST levels in both CCl4 and
BDL-induced liver fibrosis mice, suggestive of its protective
function in liver injury (data not shown). Taken together, all these
results thus suggested that NPLC0393 as a PP2Ca activator could
significantly attenuate liver fibrogenesis in both CCl4- and BDL-
induced liver fibrosis mice.
Discussion
In recent years, PP2C family has received an extensive research
interest for its wide implications in the critical signaling pathways
associated with human diseases [8,10–16,21,22]. PP2Ca,a
representative member of PP2C family, was determined to possess
tumor-suppressing properties [11]. However, its potential role in
fibrotic disease still remains untouched. Considering that liver
fibrogenesis is always accompanied with TGFb over-activation,
stress, HSCs excessive proliferation and severe inflammatory
response [1,6], we thus assume that PP2Ca might be also
connected with liver fibrogenesis for its negative role in TGFb,
stress, cell cycle and inflammatory signaling pathways [12–16].
Here, we demonstrated that PP2Ca activation could terminate
TGFb signaling pathway and simultaneously induce cell cycle
arrest in HSCs, leading to significant anti-fibrogenic effects both in
vitro and in vivo, although we could not exclude the possibility that
the anti-fibrotic effects of PP2Ca activation might be also
mediated by reduction of stress and inflammatory response, which
is however beyond our current study.
The crucial role of TGFb signaling in liver fibrogenesis has been
widely recognized [1,23]. Several anti-TGFb signaling pathway-
targeted strategies were recently proved effective, such as
inhibition of latent TGFb activation or prevention of TGFb
binding to its receptor [24]. These strategies, however, mainly
involved large molecular inhibitors (e.g. monoclonal antibodies
and antisense oligonucleotides) against TGFb receptor which
might block the systemic immunosuppressive effects of TGFb
[24,25]. The current anti-fibrogenic reports concerning small
molecular inhibitors of TGFb signaling are only restricted to the
inhibitors of TGFb type I receptor kinase [26–28]. In our work,
we determined that the natural product NPLC0393 as a specific
small molecular PP2Ca activator could efficiently alleviate liver
fibrosis. Therefore, our work is expected to provide new insights
into the understanding of TGFb signaling inhibition-based anti-
liver fibrogenesis research, while the discovered small molecular
PP2Ca activator NPLC0393 might be used as a potential lead
compound for anti-liver fibrotic drug discovery.
Interestingly, although Smad2 and Smad3 were both shown to
be dephosphorylated by PP2Ca [12], our study revealed that
NPLC0393 only selectively dephosphorylated Smad3 without
altering Smad2 phosphorylation. Based on the different roles of
Smad3 and Smad2 in TGFb signaling [29,30] and the fact that
Smad3, but not Smad2, mediates the liver fibrosis response [17],
we thereby propose that NPLC0393 might supply a promising
interest in the treatment of liver fibrosis with high specificity,
although the detailed mechanism of such specificity needs to be
further investigated. Additionally, consistent with the previous
report [16], we uncovered that PP2Ca overexpression or
NPLC0393 treatment not only decreased the TGFb-induced
Smad3 phosphorylation but also reduced the TGFb-induced p38
phosphorylation. Therefore, we assume that the decreased a1(I)
collagen expression induced by PP2Ca and NPLC0393 might
result from the inhibition of both TGFb-Smad3 and TGFb-p38
signaling pathways. Although TGFb1 transcription was reported
to be Smad3-dependent [17], the undetectable decrease of TGFb1
mRNA expression in NPLC0393 treated liver fibrosis mice might
be due to the other signaling pathways besides TGFb-Smad3,
which are also involved in TGFb1 expression.
As indicated, apart from blocking TGFb signaling, reducing
HSCs was also proved effective in preventing liver fibrogenesis
[31,32]. Here, we determined that PP2Ca activation induced cell
cycle arrest of HSCs through decreasing P-Cdk2, thus leading to
the evident antifibrotic effects as evaluated in CCl4- and BDL-
induced mouse models. By considering the well characterized anti-
proliferative effects of PP2C family members [22], we thus
suggested that our findings might gain insights into their potential
roles in the treatment of fibrotic diseases that are always associated
with excessive proliferation of activated stellate cells.
To confirm the function of PP2Ca activation on liver
fibrogenesis in mice, we carried out two mice models. One is
toxic fibrosis model induced by CCl4 and the other is biliary
fibrosis model induced by BDL. These two models are mediated
Table 1. Selectivity of NPLC0393 against a panel of
phosphatases in vitro.
Phosphatases activity (% of control)
PP2Ca 170
PP1 99
PP2A 92
PTP1B 105
doi:10.1371/journal.pone.0014230.t001
Figure 2. Identification of NPLC0393 as a small molecular PP2Ca activator. (A) Chemical structure of NPLC0393. (B, C) NPLC0393 activated
the recombinant human PP2Ca activity using pNPP (B) and phosphopeptide FLRTpSCG (C) as substrates. Data are expressed as the mean 6 S.D. of
three independent experiments. (D) Binding affinity of NPLC0393 to PP2Ca as evaluated by Biacore 3000. Sensorgrams obtained from NPLC0393
injection over the immobilized PP2Ca surface. NPLC0393 was injected for 60s, and dissociation was monitored for more than 120s. (E) ITC analysis of
NPLC0393/PP2Ca interaction.
doi:10.1371/journal.pone.0014230.g002
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with inflammatory response which activates HSCs leading to the
eventual accumulation of ECM, while the production of ECM in
the BDL-induced model is not from inflammatory response which
is not so evident in these mice [33,34]. Notably, our current study
has revealed that activation of PP2Ca reduced a-SMA expression,
collagen deposition and HYP level in both models, further
suggesting that PP2Ca activation exhibited efficient antifibrogenic
effects.
To date, quite few compounds targeting PP2Ca have ever been
reported although the relevant catalytic mechanism and crystal
structure regarding this phosphatase have been elucidated
[19,35,36]. Considering the potent biological functions of PP2Ca,
we randomly screened our in-house natural product library
(,10,000 compounds) against the recombinant human PP2Ca
phosphatase for identifying small molecular PP2Ca regulators
(inhibitor or activator). The natural product NPLC0393 was thus
determined as a specific PP2Ca activator. It should be also pointed
out that the mRNA and protein levels of PP2Ca in HSCs were not
affected by NPLC0393 (data not shown), further suggesting that
NPLC0393 implemented its antifibrotic effects through enhancing
PP2Ca enzymatic activity. NPLC0393 is a triterpene saponin
extracted from Gynostemma pentaphyllum, which is widely used in the
treatment of liver disease [37–40]. Our findings are thus expected
to bring new insights into the potential pharmacological
mechanism for this popular traditional herbal medicine, while
NPLC0393 might represent a lead compound for antifibrogenic
drug development.
Conclusively, our work has indicated that PP2Ca activation not
only terminated TGFb-Smad3 and TGFb-p38 signaling pathways
but also inhibited cell proliferation in hepatic stellate cells. The fact
that PP2Ca activation by NPLC0393 remarkably prevented liver
Figure 3. NPLC0393 reduced TGFb-Smad3 and TGFb-p38 phosphorylations in HSCs. (A,B) LX-2 cells and the isolated primary rat HSCs were
treated with increasing concentrations of NPLC0393 for indicated time points. Cells were harvested and the total cell extracts were analyzed by
western blotting. (C) LX-2 cells were treated with NPLC0393 for 48 h followed by TGFb (1ng/ml) stimulation for another 1 h. Effects of NPLC0393 on
the nuclear translocation of P-Smad3 were assessed by Immunofluorescence experiment. Images were taken by IN Cell Analyzer 1000 and quantified
by counting six random chosen fields in each well. Each treatment was performed in three wells.
#P,0.001 compared with non-TGFb-treated group;
**P,0.01; ***P,0.001 compared with TGFb-treated group with vehicle treatment.
doi:10.1371/journal.pone.0014230.g003
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confirmed that PP2Ca activation could be a promising strategy
for treating liver fibrosis.
Materials and Methods
Ethics statement
All the animal related procedures were performed according to
the ethical guidelines of Animal care and use committee, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences. Permit
numbers: SCXK (HU) 2007-0005; SYXK (HU) 2008-0049. This
study was approved by Science and Technology Commission of
Shanghai Municipality.
Animals
C57/BL6 male mice at 8-week age were obtained from
Shanghai SLAC Laboratory Animal Co. Ltd. The CCl4-induced
liver fibrosis was generated by intraperitoneal injection of CCl4
(0.5 ml/kg, diluted 1:10 in olive oil) twice weekly, alternating with
an isovolumetric dose of 5% ethanol diluted in PBS 5 times per
week [2]. NPLC0393 was dissolved in Tween-80 and intraperi-
toneal injected daily. Groups were as follows (n=9): mice given
olive oil and NPLC0393 (control); mice given CCl4, ethanol and
Tween-80 (model); mice given CCl4, ethanol and treated with
2.5 mg/kg of NPLC0393 (NPLC0393). After 4 weeks, animals
were starved overnight and executed 48 h after the last CCl4
injection.
Figure 4. NPLC0393 decreased TGFb-induced a1(I) collagen expression in HSCs. (A) LX-2 cells and the isolated primary rat HSCs were
treated with increasing concentrations of NPLC0393 for 48 h. Cells were harvested for real-time PCR experiment. ***P,0.001 compared with vehicle
group. (B) LX-2 cells were treated with NPLC0393 and TGFb for 48 h, cells were then harvested and the total RNA was extracted.
#P,0.001 compared
with non-TGFb-treated group; **P,0.01; ***P,0.001 compared with TGFb-treated group with vehicle treatment. (C) Characterization of stable LX-2
cell line expressing shPP2Ca by western blot analysis (upper panel). Control and shPP2Ca cells were treated with increasing concentrations of
NPLC0393 for 24 h and harvested for Western blotting (lower panel). (D) Control and shPP2Ca cells were treated with NPLC0393 and TGFb for 48 h
and harvested for western and real-time PCR analysis. Significant difference of the reduction on a1(I) procollagen mRNA by NPLC0393 in shPP2Ca
cells versus that in control cells, *P,0.05.
doi:10.1371/journal.pone.0014230.g004
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the common bile duct between two ligations after midline
laparotomy as described [2]. Groups were as follows (n=9): mice
receiving sham operation and Tween-80 (control); mice receiving
BDL and Tween-80 (model); mice receiving BDL and treated with
NPLC0393 (NPLC0393). Mice were sacrificed after 2 weeks. Liver
samples were either fixed in buffered formalin or snap frozen in
liquid nitrogen and stored at 280uC until use.
Histological and immunohistochemical analysis
Livers were fixed in 4% paraformaldehyde, embedded in
paraffin and sectioned. Immunohistochemical staining of a-SMA
was performed to quantify activated HSCs. Masson staining for
collagen was used to quantify fibrosis area. The results were
analyzed by Image-Pro Plus software (MediaCybernetics, France).
Images of five fields were taken for each section with 9 mice in
each group.
Figure 6. NPLC0393 attenuated CCl4- and BDL-induced a-SMA expressions in vivo. (A) Expression of a-SMA in CCl4- and BDL-intoxicated
mice was evaluated by immunohistochemical staining, and quantified by counting five random chosen high-power fields. Scale bar, 50 mm. n=9 for
control (CTL), model (MOD) and 2.5 mg/kg NPLC0393-treated (NPLC0393) mice. (B) a-SMA expression was also assessed by western blotting and
quantified from three independent experiments, *P,0.05, **P,0.01. n=3 for control (CTL), model (MOD) and 2.5mg/kg NPLC0393-treated
(NPLC0393) mice.
doi:10.1371/journal.pone.0014230.g006
Figure 5. NPLC0393 induced cell cycle arrest in HSCs. (A,B) LX-2 cells and the isolated primary rat HSCs were treated with increasing
concentrations of NPLC0393 for the indicated time points. MTT assay was performed to assess the effects of NPLC0393 on cell viability. The values
were indicated as relative units normalized to the control. *P,0.05; **P,0.01; ***P # 0.001 compared with control group at the indicated time point.
(C, D) LX-2 cells were exposed to increasing concentrations of NPLC0393 for 48 h. Then cells were harvested and the cell-cycle distribution was
analyzed by Flow cytometry analysis. (E) LX-2 cells were treated as described in Figure 3C. Effect of NPLC0393 on Cdk2 phosphorylation was assessed
by western blotting. For the PDGF-induced Cdk2 phosphorylation, LX-2 cells were cultured to confluence and growth-arrested for 24 h in DMEM with
10% FBS, and then for an additional 24 h treatment with NPLC0393 and PDGF (10 ng/ml) in DMEM plus with 0.2% FBS. (F) Control and shPP2Ca cells
were treated with increasing concentrations of NPLC0393 for 24 h. Effects of NPLC0393 on cell viability in shPP2Ca cells and control cells were
assessed by MTT assay. Significant difference of the reduction on cell viability by NPLC0393 in shPP2Ca cells versus that in control cells at indicated
dose, *P,0.05, **P,0.01. (G) Cells were treated as described in Figure 3F and harvested for Western blotting.
doi:10.1371/journal.pone.0014230.g005
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Hepatic hydroxyproline content was measured using hydroxy-
proline detection kit (Jiancheng Institute of Biotechnology,
Nanjing, China) according to the manufacturer’s instruction.
The results (mg/mg liver) were calculated according to the
standard curve of hydroxyproline.
Primary HSCs isolation, cell lines, culture and treatment
Primary HSCs were isolated from normal rat liver (male
Sprague–Dawley rats, 400–450 g) as described [41]. Cells were
cultured in Dulbecco’s minimum essential medium (DMEM;
GIBCO/Invitrogen) containing 10% fetal bovine serum (FBS;
GIBCO/Invitrogen). All the experiments were performed using 6-
Figure 7. NPLC0393 attenuated CCl4- and BDL-induced collagen expressions in vivo. (A) Collagen deposition in livers was evaluated by
Masson staining and determined by image quantification. Scale bar, 100 mm. (B) Collagen mRNA expression was examined by real-time PCR analysis.
***P # 0.001, n=3 for control (CTL), model (MOD) and 2.5 mg/kg NPLC0393-treated (NPLC0393) mice. (C) Hydroxyproline content in liver was also
measured. Significant difference versus model group, *P,0.05. n=9 for control (CTL), model (MOD) and 2.5 mg/kg NPLC0393-treated (NPLC0393)
mice.
doi:10.1371/journal.pone.0014230.g007
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SMA expression using western blotting. Human hepatic stellate
cell line LX-2 [42] and HEK293T Phoenix-ampho retrovirus
packaging cells (ATCC) were cultured in DMEM supplemented
with 10% FBS in 5% CO2 at 37uC. TGFb and PDGF were from
Sigma.
Cell transfection
Human PP2Ca and shPP2Ca494 (for PP2Ca expression knock
down assay) were electransfected into LX-2 cells as described [43]
using AmaxaH Cell Line NucleofectorH Kit T (Lonza).
Establishment of stable LX-2 cell line expressing shPP2Ca
pSRG vector and pSRG-shPP2Ca494 construct were trans-
fected into 293T Phoenix-ampho retrovirus packaging cells. After
48 h, viral supernatant was collected, filtered, and supplemented
with polybrene (8 mg/ml). LX-2 cells were infected with viral
supernatant. At 48h post-infection, infected cells were selected
with puromycin (3 mg/ml). After selection for 5 days, cells were
collected and verified by western blotting [12].
Cell viability assay
Cell viability was evaluated using MTT (Sigma) assay as
previously described [44].
Cell cycle analysis
Cell cycle was analyzed as previously described [44]. The
samples were assayed with a FACS Calibur instrument and the
data were analyzed with CellQuest 3.1 Software.
Nuclear translocation
Nuclear translocation was assessed by immunofluorescence
experiment as described [25]. The images were taken by IN Cell
Analyzer 1000 and the data were analyzed with Nuclear
Translocation analysis module [45].
Western blotting
Primary antibodies used were phospho-Smad3 (Ser423/425),
Smad3, phospho-Smad2 (Ser465/467), Smad2, phospho-p38
(Thr180/Tyr182), p38, phospho-Cdk2 (Thr160) and Cdk2 (Cell
Signaling Technology), PP2Ca (Abcam), a-SMA (BOSTER,
China), Collagen a1 Type I (Santa cruz), GAPDH (KangChen,
China). Western blotting was performed according to the
manufacturers’ instructions.
Real-time PCR
Extraction of total RNA and synthesis of complementary cDNA
were performed as described [46]. Real-time PCR was performed
using SYBR Premix Ex Taq (TaKaRa) on DNA Engine Opticon
TM2 System (MJ Research, Waltham, MA, USA). The primer
pairs for human b-actin, human a1(I) procollagen, rat 18S were
designed as described [2,42]. The primer pairs for rat procollagen
a1(I): 59CACTCAGCCCTCTGTGCC39 (sense) and 59 AC-
CTTCGCTTCCATACTCG 39 (antisense). The primer pairs for
mouse procollagen a1(I): 59ACGGCTGCACGAGTCACAC39
(sense) and 59GGCAGGCGGGAGGTCTT39 (antisense).
The PCR cycle was 95uC for 5 seconds, 58uC for 20 seconds
and 72uC for 20 seconds.
Identification of human PP2Ca activation by NPLC0393
NPLC0393 was isolated and purified as previously described
[47]. Human PP2Ca was expressed in E. coli with C-terminal 6-
His tag, and batch-purified using Ni-NTA resin according to the
manufacturer’s instruction (Qiagen). The assay was carried out in
a reaction buffer containing 50 mM Tris-HCl, pH 7.0, 10 mM
MnCl2 [19]. NPLC0393 was dissolved in DMSO as a stock
solution and diluted in reaction buffer to the final concentration.
PP2Ca was diluted in reaction buffer as appropriate to 10 mg/ml,
and reactions were started by the addition of 4 mM pNPP (Sigma),
incubated with varying concentrations of NPLC0393 for 2 h at
room temperature, and stopped with a solution containing 1 N
NaOH. The effect of NPLC0393 on PP2Ca dephosphorylation of
pNPP was determined by monitoring the absorbance change
recorded at 410 nm, with 1% DMSO as a control.
With phosphopeptide FLRTpSCG (HD Biosciences; China) as
the substrate [14], the reaction buffer containing 50 mM Tris-
HCl, pH 7.0, 30 mM MgCl2 was used. PP2Ca was diluted in
reaction buffer as appropriate to 10 mg/ml and incubated with
varying concentrations of NPLC0393 for 2 h at room tempera-
ture. Then the reaction was started with 500 mM FLRTpSCG for
30 min and terminated by adding 100 ml of malachite green/
ammonium molybdate reagent (upstate). Color development was
allowed to proceed for 15 minutes at room temperature.
Measurements were taken at 630 nm using microplate spectro-
photometer (Bio-Rad). The effect of NPLC0393 on PP2Ca
dephosphorylation of FLRTpSCG was determined by monitoring
the absorbance change recorded at 630 nm, with 1% DMSO as
control.
For selectivity assay, PP1 and PP2A were bought from Upstate.
PTP1B was purified using Ni-NTA resin according to the
manufacturer’s instruction (Qiagen). The effects of NPLC0393
on these phosphatases dephosphorylation of pNPP were deter-
mined by monitoring the absorbance change recorded at 410 nm,
with 1% DMSO as a control.
Surface plasmon resonance (SPR) technology based
assay
The binding affinity of NPLC0393 to PP2Ca was evaluated by
using a Biacore 3000 instrument (Biacore AB, Uppsala, Sweden).
Immobilization of the purified PP2Ca to the hydrophilic
carboxymethylated dextran matrix of the sensor chip CM5
(Biacore) was performed by the standard primary amine coupling
reaction. PP2Ca (8.28 mg/mL in 10 mM sodium acetate, pH 4.2)
was then injected over the surface until a desired immobilization
level (6000 RU) was reached. Binding affinity measurements were
carried out in a continuous flow of 20 ml/min HBS (10 mM
HEPES, 150 mM NaCl and 0.005% (v/v) surfactant P20, pH 7.4)
as the running buffer. NPLC0393 was diluted in the running
buffer and automatically injected in a series of increasing
concentrations. The binding responses were recorded continuously
in resonance units (RU) at a frequency of 1 Hz as sensorgrams and
presented as a function of time. Sensorgrams were processed by
using automatic correction for nonspecific bulk refractive index
effects. The dissociation equilibrium constant (KD) was estimated
by the 1:1 Langmuir binding fit model encoded in the Biacore
analysis software.
Isothermal Titration Calorimetry (ITC) technology based
assay
Binding of NPLC0393 to PP2Ca was also measured at 25uCb y
using a VP-ITC calorimeter (MicroCal, Northampton, MA). All
the samples were dialyzed against ITC buffer (50 mM Tris-HCl,
pH 7.0 and 1 mM Mn
2+) and degassed prior to titration. 1.43 ml
of 50 mM PP2Ca was titrated by 300 ml of 500 mM PP2Ca using
30 injections. The heat of dilution of NPLC0393 was measured by
titrating NPLC0393 into the ITC buffer and was subtracted for
PP2Ca Prevents Liver Fibrosis
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(MicroCal) using a single-site binding model.
Statistical analysis
All the experiments were repeated at least three times. Data
were presented as mean 6 SD. Statistical analysis was performed
using one-way ANOVA followed by Bonferroni’s multiple
comparison tests. p value of less than 0.05 was considered
statistically significant.
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